William Blair analyst Matt Phipps has maintained their bullish stance on GMAB stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Matt Phipps has given his Buy rating due to a combination of factors, primarily focusing on Genmab’s promising developments in their oncology pipeline. The presentation of updated data for Rina-S at the 2025 European Society for Medical Oncology Congress highlighted its potential as a leading therapy in endometrial cancer, particularly with its first-mover advantage in the topoisomerase-based ADC market for platinum-resistant ovarian cancer. This strategic positioning is expected to provide Genmab with a competitive edge in the evolving treatment landscape.
Additionally, the promising response rates observed in the updated clinical data reinforce confidence in Rina-S’s efficacy and long-term value. The company’s ability to maintain a strong pipeline with significant advancements in treatment options for difficult-to-treat cancers supports the Buy rating, as these factors are likely to drive future growth and shareholder value.